AgomAb Therapeutics NV — Company profile
Healthcare · Biotechnology · Belgium
Last price 7.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 368.87M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Details
| Name | AgomAb Therapeutics NV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 62 |
| Founded | 2017 |
| Ipo Date | 2026-02-06 |
| Ceo | Tim Knotnerus |
| Country | Belgium |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| Ipo Price | 16.00 |
| Isin | US00860C1027 |
| Cusip | 00860C102 |
| Cik | 2020932 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Tim Knotnerus MSc, Ph.D. | Chief Executive Officer and Executive Director |
| Paolo Michieli Ph.D. | Founder, Senior Advisor and Member of Scientific Advisory Board |
| Pierre Kemula B.Sc. | Chief Financial Officer |
| Sofie Van Gijsel | Vice President of Investor Relations |
| Ellen Lefever | General Counsel |
| Dr. Philippe Wiesel M.D. | Chief Medical Officer |
| Dr. Paul Van Der Horst Ph.D. | Chief Business Officer |
| Dr. Andrea Sáez Borderías Ph.D. | Chief Development Officer |
Contact
| Address | Posthoflei 1/6, Antwerp, 2600, Belgium |
| Phone | 32 3 318 91 70 |
| Website | https://www.agomab.com |